What “eliminating middlemen” actually means
Y Combinator’s Summer 2024 Request for Startups highlighted a straightforward but difficult opportunity: remove unnecessary layers between patients, healthcare professionals, suppliers, and payment. The idea is still relevant in 2026, but founders should interpret it carefully. Not every intermediary is wasteful. Insurers, distributors, claims administrators, pharmacies, diagnostic networks, and care coordinators can perform useful functions. The opportunity is to replace opaque, repetitive, and low-value intermediation with better software, transparent pricing, and direct relationships.
For Indian startups, this distinction matters. Healthcare is fragmented across public and private providers, urban and rural markets, languages, payment methods, and levels of digital maturity. A product that removes one layer for a premium urban consumer may be far less valuable than a product that reduces coordination costs for a district hospital, independent clinic, or community health worker.
Where the friction sits in India’s healthcare chain
A strong startup thesis begins with a specific workflow rather than the broad claim that healthcare is inefficient. Common sources of avoidable friction include:
- Patient discovery: Patients struggle to compare providers, availability, quality signals, and total prices.
- Referrals: Paper records, phone calls, and disconnected systems slow movement between primary, secondary, and specialist care.
- Claims and authorisation: Providers spend time assembling documents, checking eligibility, and following up with payers.
- Diagnostics: Orders, sample collection, reports, and follow-up are often handled by separate systems.
- Medicines: Patients may face inconsistent prices, stock-outs, and confusing substitution decisions.
- Provider administration: Small clinics lack the staff and software to manage scheduling, billing, records, and patient communication efficiently.
- Data exchange: Patients repeatedly provide the same information because systems cannot share usable, consented records.
The best opportunities usually have three characteristics: a frequent transaction, a clearly identifiable budget owner, and measurable savings or faster care. “Making healthcare better” is not enough. A founder should be able to show which manual step disappears, who benefits, and who pays for the product.
High-potential startup models
1. Direct primary care and specialist access
A platform can connect patients directly to clinicians for suitable consultations, follow-ups, chronic-care monitoring, and second opinions. The product must go beyond a video call. Useful differentiation may include local-language intake, structured clinical summaries, appointment coordination, prescription workflows, and escalation to in-person care.
For India, a hybrid model is often more credible than a digital-only promise. Combine teleconsultation with neighbourhood clinics, diagnostic partners, pharmacies, or mobile health teams. This reduces unnecessary referrals while preserving a physical care pathway when examination or testing is required.
2. Provider-led purchasing and transparent pricing
Independent clinics and small hospitals often pay fragmented prices for equipment, consumables, diagnostics, software, and staffing. A procurement or operating platform can aggregate demand, provide reliable fulfilment, and disclose its margin instead of hiding it in a complex distribution chain.
The model should avoid simply becoming another opaque marketplace. Publish service levels, product substitutions, delivery timelines, and total landed costs. If the startup takes a commission, explain what the commission funds and whether it changes the provider’s or patient’s price.
3. Claims, billing, and prior-authorisation automation
Administrative work is one of the clearest areas where software can replace repetitive intermediation. A product might extract information from clinical notes, check policy rules, generate claim packets, identify missing documents, and track exceptions for a human operator.
The winning product is not necessarily fully autonomous. In healthcare, a human-in-the-loop workflow can be safer and easier to sell. Measure results through claim turnaround time, rejection rates, staff hours saved, and patient out-of-pocket surprises. Integrate with existing hospital systems rather than requiring providers to rebuild their operations.
4. Patient-controlled records and consented data exchange
A patient should not have to carry a file from one provider to another or repeat a medical history at every visit. Products built around interoperable records, consent management, and portable clinical summaries can reduce dependency on institutional data silos.
Founders should treat privacy as a product requirement, not a later compliance task. Use clear consent flows, role-based access, audit logs, data minimisation, and deletion or retention policies appropriate to the service. India’s digital public infrastructure can create distribution opportunities, but interoperability does not remove the need for clinical validation and accountable data governance.
5. Rural and multilingual care coordination
Removing middlemen does not always mean removing people. In rural healthcare, frontline workers, local pharmacists, and community organisations may be essential trust and access points. The better goal is to equip them with tools that reduce paperwork and improve escalation.
AI can help with local-language intake, summarising patient histories, identifying missing information, and routing cases to the right clinician. It should not silently diagnose or prescribe beyond its validated scope. Founders exploring this space should study AI solutions for rural healthcare in India and design for intermittent connectivity, low-end devices, assisted use, and voice-first interaction.
How to use AI without creating a new middleman
AI is useful when it removes repetitive coordination, not when it adds an impressive interface around the same broken workflow. Practical applications include:
- Converting voice or chat inputs into structured intake forms.
- Summarising records for clinicians before a consultation.
- Matching patients to available providers based on need, location, language, and urgency.
- Detecting duplicate billing, missing claim evidence, or inconsistent documentation.
- Translating instructions into Indian languages while preserving medical meaning.
- Categorising patient feedback and identifying recurring service failures.
A rapid prototype can test workflow fit before a startup invests in deep integrations. Teams can use rapid AI prototyping services for startups to validate intake, routing, or summarisation flows, then harden the system with clinical review, monitoring, and secure infrastructure. For multilingual products, building multilingual chatbots for Indian startups offers a useful starting point, but healthcare deployments require stronger escalation and audit controls than ordinary customer support.
Computer vision may help with document extraction, diagnostic assistance, or remote assessments, but it should be introduced only where the input quality, clinical workflow, and liability model are understood. See integrating computer vision in healthcare apps for a practical framework.
Compliance and trust are part of the moat
Healthcare startups operate in a high-consequence environment. Before launching, map the product against applicable Indian requirements, including data protection obligations, clinical establishment rules, telemedicine guidance, medical-device classification where relevant, and contractual requirements imposed by hospitals or insurers. Obtain specialist legal and clinical advice rather than relying on generic startup templates.
Build these controls early:
- Explicit, understandable patient consent.
- Encryption in transit and at rest.
- Strong authentication and least-privilege access.
- Immutable audit trails for record access and changes.
- Human review for high-risk recommendations.
- Incident response and breach notification procedures.
- Clear explanations of pricing, commissions, and clinical limitations.
Trust is not a marketing layer. It determines whether clinicians adopt the product, whether institutions permit integration, and whether patients continue using it after the first interaction.
A practical validation plan for founders
Start with 20-30 interviews across patients, clinicians, administrators, and the payer or employer who may fund the product. Ask respondents to reconstruct the last time the problem occurred. Avoid asking whether they “like the idea”; document time spent, money lost, delays, workarounds, and existing software.
Then run a narrow pilot:
1. Select one workflow, such as claim submission, referral coordination, or diagnostic follow-up.
2. Define a baseline using real operational metrics.
3. Secure a clinical or operational champion inside the customer organisation.
4. Test with limited data and clear human review.
5. Compare turnaround time, error rates, adoption, and total cost.
6. Charge early if the product affects a real budget.
A credible YC application should explain the customer, the broken workflow, the wedge, early evidence, and why this team can solve the problem. Avoid claiming that you will remove all insurers, hospitals, or pharmacies. Explain precisely which transaction becomes more direct and why the resulting system is safer, cheaper, or faster.
Business models that align incentives
Possible models include provider subscriptions, per-transaction fees, employer or insurer contracts, shared savings, care-program memberships, and infrastructure licensing. Be cautious with referral commissions and lead-generation models: they can recreate the conflicts and opacity the startup claims to remove.
The strongest businesses make the payer’s gain visible. A hospital may pay for fewer rejected claims; an employer may pay for faster access and lower absenteeism; a patient may pay for transparent, convenient chronic care; a clinic may pay for reduced administrative workload. Pick one initial buyer and prove value before expanding across the ecosystem.
The founder’s test
The core question is not, “Can technology remove this middleman?” It is: Does the proposed product reduce a real coordination cost without weakening safety, accountability, or access? Start with one painful transaction, preserve necessary expertise, make incentives transparent, and measure the outcome. That is the practical interpretation of Y Combinator’s healthcare thesis for Indian builders in 2026.